Viatris Inc.

VTRSsupplier

Viatris is a global pharmaceutical company formed from the 2020 merger of Mylan and Pfizer's Upjohn division, focused on expanding access to generic and biosimilar medicines worldwide.

⇄ Compare

产品与营收

产品营收占比

营收构成 ($15.0B)

静态数据（加载实时财务…）

Developed Markets (45%)

Emerging Markets (30%)

Greater China (12%)

JANZ (Japan, Australia, NZ) (13%)

业务板块构成与主要客户

产品详情

Branded Generics35%

Off-patent branded drugs sold primarily in emerging markets

Complex Generics & Biosimilars25%

Biosimilar versions of Humira, Herceptin, and complex injectables

Generic Pharmaceuticals25%

Standard generic drugs for developed markets

Legacy Brands (Lipitor, EpiPen)15%

Heritage branded products from Pfizer Upjohn and Mylan

供应链关系

合作伙伴

Pfizer Inc.

Legacy Pfizer Upjohn product portfolio

影响: Medium — spun off from Pfizer

竞争对手

AbbVie Inc.

Biosimilar Humira competition

影响: Medium — biosimilar erosion of Humira

主要客户

Walgreens Boots Alliance

Generic drug retail distribution

影响: Medium — pharmacy channel

宏观与市场背景

제약 / 바이오行业新闻

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

近期催化剂

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI 分析

点击「获取 AI 分析」以获得 Viatris Inc. 的 AI 供应链分析。

企业信息

总部

Canonsburg, Pennsylvania, USA

成立时间

2020

员工人数

37,000+

官网

viatris.com

行业概况 — 제약 / 바이오

行业新闻